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Cells of the immune system respond to sex
hormones, including estrogen (McMurray
2001). Upon binding of estrogen to the estro-
gen receptor (ER), the ligand–receptor com-
plex dimerizes and mediates the transcriptional
activity of genes containing estrogen response
elements (EREs) and/or AP-1 sites. Recent
studies detected ER-α in murine splenic B and
T cells by both ﬂuorescent activated cell sort-
ing analysis and reverse-transcriptase poly-
merase chain reaction (Sakazaki et al. 2002).
Additionally, Grimaldi et al. (2002) identiﬁed
the more recently described ER-β in murine
splenic B cells. It remains unclear whether
ER-β is expressed in murine splenic T cells.
Estrogen has been shown to alter cytokine pro-
duction and T-cell subset distribution (Ahmed
et al. 1985; Correale et al. 1998). Both inter-
feron-γ (IFN-γ) and interleukin-10 (IL-10)
are modulated by estrogen (Kanda and
Tamaki 1999; Karpuzoglu-Sahin et al.
2001). The IFN-γ promoter contains ERE-
like sequences, and estrogen reportedly up-
regulates IFN-γ production (Fox et al. 1991).
In addition to modulating EREs, estrogen
may modulate the expression of genes through
AP-1 sites, sites found in many cytokine gene
promoters, including IFN-γ (Kushner et al.
2000). Both ER subtypes interact with Fos
and Jun elements at AP-1 sites, but with
opposite outcomes (Paech et al. 1997).
Estrogen provides a possible link between
cytokines and the autoimmune disorder sys-
temic lupus erythematosus (SLE), because
both IFN-γ and IL-10 have been implicated in
lupus (Csiszar et al. 2000; Gonzalez-Amaro
et al. 1998). Lupus occurs at a ratio of > 8:1 in
females compared with males and commonly
strikes in women during the childbearing years
when circulating estrogen levels are highest
(Kotzin 1996). SLE is characterized by high
levels of IgG autoantibodies, including
anti–double-stranded DNA (anti-dsDNA)
autoantibodies. Female NZB × NZW F1
(NZB/NZW) mice spontaneously develop a
disease comparable with human lupus, display-
ing glomerulonephritis, arthritis, and elevated
levels of IgG autoantibodies, in particular the
complement-activating IgG2a class (Zeng et al.
2000). The reduced average life span of female
NZB/NZW mice of 40 weeks compared with
64 weeks in males implicates female sex hor-
mones in the disease process (Walker et al.
1996). In mice, IgG2a antibodies contribute
to the glomerulonephritis observed in female
NZB/NZW mice, and isotype switching to
IgG2a is IFN-γ dependent (Haas et al. 1997).
Several studies indicate a role for IFN-γ in
murine lupus: IFN-γ treatment leads to a
worsening of disease in NZB/NZW mice, and
glomerulonephritis is ameliorated both in
IFN-γ receptor knockout mice and in
NZB/NZW mice treated with soluble IFN-γ
receptor (Haas et al. 1998; Hasegawa et al.
2002; Ozmen et al. 1995).
Bisphenol A (BPA) is produced by the
acid-catalyzed reaction of acetone and phenol
and is widely used in the manufacture of poly-
carbonate plastics and epoxy resins found in
containers used to package food (Ben-Jonathan
and Steinmetz 1998). Although structurally
different from estrogen, BPA binds to both
ER subtypes and with 6-fold greater afﬁnity to
ER-β (Bolger et al. 1998; Pennie et al. 1998).
Luciferase reporter assays indicate that BPA
may either mimic or antagonize the effects of
estrogen, depending on both the cell type and
the ER isotype bound (Kurosawa et al. 2002).
In vitro BPA exposure stimulates breast cancer
cell lines to proliferate, increases progesterone
receptor expression in a uterine cell line, and
induces c-fos gene expression (Bergeron et al.
1999; Schafer et al. 1999; Steinmetz et al.
1998). Several in vivo studies document
reproductive effects of low-dose BPA expo-
sure. Microgram quantities of BPA were
shown to be estrogenic in F344 rats by
increasing prolactin expression (Steinmetz
et al. 1997). Male offspring of BPA-treated
pregnant mice showed increased prostate size
and decreased epididymal weight (Gupta
2000; Nagel et al. 1997). A review of these
studies led the Endocrine Disruptors Low-
Dose Peer Review Panel to cautiously conﬁrm
that exposure to very low doses of BPA can
cause biologic effects (Kaiser 2000).
Few reports have appeared concerning
BPA and immune function. In vitro, BPA has
been shown to inhibit lymphocyte mitogene-
sis (Sakazaki et al. 2002), MCP-1 production
(Inadera et al. 2000), and macrophage adhe-
sion (Segura et al. 1999). Our study differs in
that we investigated BPA modulation of
immune function in vivo. We were interested
in observing the effects of oral exposure to
BPA in normal and lupus-prone mice. As
recently reported, mouse strains differ in their
sensitivity to estrogen (Spearow et al. 1999).
For our studies, we initially used the estrogen-
sensitive, nonautoimmune C57BL/6 strain.
To determine the effects of BPA in a lupus
model, we fed BPA to 5-week-old, female
NZB/NZW mice and analyzed IFN-γ and
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To investigate the effects of the estrogen receptor-binding molecule bisphenol A (BPA) on murine
immune function in vivo, we fed a low dose of 2.5 µg BPA/kg body weight/day to both normal
C57BL/6 and lupus-prone NZB × NZW F1 (NZB/NZW) 5-week-old mice for 1 week. Analysis
of concanavalin A (ConA)-stimulated splenic mononuclear cells by ELISA demonstrated that
BPA-fed C57BL/6 males produced, on average, 40% less interferon-γ (IFN-γ; p < 0.01) and
C57BL/6 females 28% less IFN-γ (p < 0.05) compared with controls. Treated female NZB/NZW
mice were monitored for lupus disease symptoms, deﬁned as proteinuria (> 100 mg/dL albumin
in urine for 2 consecutive weeks). Before the development of proteinuria, BPA-fed NZB/NZW
mice produced signiﬁcantly less ConA-stimulated IFN-γ than did controls and displayed an aver-
age reduction of 50% in immunoglobulin G2a (IgG2a) antibody production from lipopoly-
saccharide (LPS)-stimulated splenocytes (p < 0.05). It is striking that 5-week-old female
NZB/NZW mice fed a 7-day low-dose course of BPA developed proteinuria an average of 7 weeks
later than did controls. Once proteinuria developed, splenocytes were stimulated with ConA for
cytokine analysis. The BPA-fed mice showed a dramatic reduction of 64% in IFN-γ production
and a 32% reduction in ConA-stimulated interleukin-10 (p < 0.05). The long-lasting effects of
BPA on IFN-γ and IgG2a production likely contributed to the increased symptom-free period of
the NZB/NZW mice. Key words: bisphenol A, C57BL/6, estrogen receptor, IgG2a, interferon-γ,
lupus, NZB × NZW. Environ Health Perspect 111:1883–1887 (2003). doi:10.1289/ehp.6359
available via http://dx.doi.org/ [Online 29 August 2003]
Research | ArticleIL-10 release, IgG2a antibody production,
and the development of proteinuria. IFN-γ
produced from stimulated cells was reduced in
both C57BL/6 and NZB/NZW mice treated
with BPA. In addition, BPA modulated IgG2a
production and delayed the onset of lupus
symptoms in NZB/NZW females.
Materials and Methods
Mice. We obtained 3- to 4-week-old C57BL/6
mice from Taconic (Germantown, NY).
Initially, we purchased 3- to 4-week-old female
NZB × NZW F1 (NZB/NZW) mice from
Jackson Laboratory (Bar Harbor, ME). Because
of production difﬁculties and unavailability of
female NZB/NZW mice at Jackson Labs, we
also purchased 3- to 4-week-old female
NZB/NZW mice from Harlan (Indianapolis,
IN). All mice were housed according to guide-
lines of the Institutional Animal Care and Use
Committee. 
For the in vivo studies, mice were housed
individually. At 5 weeks of age, either
C57BL/6 or NZB/NZW mice were weighed
daily and fed 2.5 µg BPA/kg body weight
(bw)/day (Sigma, St. Louis, MO) diluted in
phosphate-buffered saline (PBS), in a cereal
treat, for 7 days. Control mice of the same age
were weighed and fed PBS in a cereal treat for
7 days. Mice were observed to consume the
entire dose daily. C57BL/6 mice were sacri-
ﬁced by CO2 overdose within 2–4 days of the
last BPA dose, and the spleens were aseptically
removed.
After in vivo exposure to BPA at 5 weeks of
age, female NZB/NZW mice were monitored
for lupus disease symptoms by measuring pro-
tein levels in urine using Albustix (Fisher
Scientific, Pittsburgh, PA). Proteinuria was
deﬁned as > 100 mg/dL of protein in urine for
2 consecutive weeks (Zeng et al. 2000). Mice
testing positive for proteinuria were immedi-
ately sacriﬁced, and splenic mononuclear cells
were isolated. To assess the effects of BPA
exposure in mice before the onset of protein-
uria, NZB/NZW mice with < 100 mg/dL of
protein in urine were sacrificed between the
ages of 8 and 19 weeks.
Preparation of mononuclear cells.
Mononuclear cells were isolated from spleens
using aseptic technique by grinding through a
mesh sieve followed by density centrifugation
on Lympholyte (Accurate Chemical &
Scientific Corp., Westbury, NY). Cells were
counted by either trypan blue exclusion using
a hemacytometer or, in some cases, using
ViaCount stain (Guava Technologies,
Hayward, CA) containing the intact cell–
impermeant nucleic acid dye 7-AAD (Schmid
et al. 1992). The viability of the mononuclear
cells was typically > 95%.
Cell culture conditions. For in vitro expo-
sure to BPA, splenic mononuclear cells were
resuspended in complete media: RPMI-1640
supplemented with 10% fetal calf serum
(Sigma), 5 × 10–5 M 2-mercaptoethanol,
0.1 mg/mL streptomycin, 100 U penicillin,
and 2 mM L-glutamine (Sigma). Cells were
stimulated in 24-well Costar plates at a concen-
tration of 4 × 106 cells/mL with a ﬁnal concen-
tration of 4.0 µg/mL concanavalin A (ConA;
Sigma). BPA was added at ﬁnal concentrations
ranging from 50 µM to 0.5 nM. Cells were
incubated in a humidiﬁed chamber with 5%
CO2 at 37°C for 24 hr. Supernatants were
harvested and analyzed by ELISA for IFN-γ.
After in vivo exposure to BPA, isolated
splenic mononuclear cells were resuspended in
complete media at a concentration of 4 × 106
cells/mL and stimulated with either a final
concentration of 4.0 µg/mL ConA or heat-
killed Staphylococcus epidermidis. An overnight
culture of S. epidermidis (optical density, 0.9 at
570 nm) was incubated at 60°C for 1 hr and
added to cells at a ﬁnal dilution of 1:20. Cells
were incubated in a humidiﬁed chamber with
5% CO2 at 37°C. After 24 hr, supernatants
were harvested and assayed for IFN-γ produc-
tion by ELISA. Optimal IL-10 levels were
detected in ConA-stimulated supernatants by
ELISA after 72 hr incubation.
Flow cytometric analysis of subsets. To
determine the percentage of B cells and T-cell
subsets, mononuclear splenic cells were stained
immediately upon isolation. Brieﬂy, cells were
incubated on ice with FcBlock (PharMingen,
San Jose, CA) and then stained with either
phycoerythrin-conjugated anti-CD4 or CD8
monoclonal antibodies (all purchased from
PharMingen and used at a ﬁnal concentration
of 2 µg/mL), anti-CD19 biotinylated mono-
clonal antibody followed by streptavidin-PE
(Guava Technologies), or isotype-matched
control antibodies (PharMingen). Live cells
were gated using 7-AAD dye exclusion (Guava
Technologies) and analyzed using a Guava
personal flow cytometer and CytoAnalysis
software (Guava Technologies).
Cytokine analysis by ELISA. Culture
supernatants were assayed for cytokine produc-
tion by ELISA following the manufacturer’s
recommended protocol (Pierce-Endogen,
Rockford, IL). In brief, 50 µL recombinant
IFN-γ standards or 24-hr culture supernatants
were added to each precoated well in duplicate.
Plates were incubated for 2 hr at room temper-
ature followed by the addition of biotinylated
anti-IFN-γ antibody. After a 1-hr room-
temperature incubation, the plate was washed,
and streptavidin-horseradish peroxidase (HRP)
solution was added to each well. The plate was
incubated for 30 min and again washed. TMB
(tetramethylbenzidine) substrate solution
(Pierce-Endogen) was added, and the plates
were developed in the dark for 30 min. Stop
solution containing sulfuric acid was added,
and absorbance was measured at 450 nm on an
EL312e plate reader (Bio-Tek Instruments,
Winooski, VT). Results were calculated from
the standard curve using Excel (Microsoft
Corporation, Redmond, WA).
To determine IL-10, we added 72-hr super-
natants or recombinant IL-10 standards to each
anti-mouse IL-10 precoated well in duplicate,
which were incubated at room temperature for
3 hr. After a wash step, biotinylated anti-IL-10
antibody was added to each well and allowed
to incubate for 1 hr at room temperature. The
remainder of the procedure is identical to that
outlined for IFN-γ.
IgG2a antibody production by ELISA.
Splenic mononuclear cells were isolated from
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Figure 1. Inhibition of ConA-induced secretion of
IFN-γ in vitro by BPA in a dose-dependent manner.
Splenic mononuclear cells from 6-week-old C57BL/6
mice were incubated with 4.0 µg/mL ConA and BPA.
IFN-γ in 24-hr culture supernatants was detected by
ELISA. The data represent the mean ± SEM of
seven mice.
*p < 0.05. **p < 0.01.
Figure 2. Decreased IFN-γ concentration in 6-week-
old C57BL/6 mice after an oral dose of 2.5 µg BPA/kg
bw/day for 7 days. Twenty-four-hour supernatants
from splenic mononuclear cells isolated 2–4 days
after the last BPA dose were stimulated with either
4.0 µg/mL ConA or heat-killed S. epidermidis and
assayed for cytokine production by ELISA. The data
represent the mean ± SEM. Numbers within the bars
indicate the number of animals per treatment. 
*p < 0.05, and **p < 0.01 by paired Student’s t-test.
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before they displayed disease symptoms (< 100
mg/dL protein in urine) and incubated in
complete media with 10.0 µg/mL lipopolysac-
charide (LPS; Sigma) at 37°C in humidified
air with 5% CO2 for 72 hr. IgG2a antibody
production was determined by isotype-speciﬁc
ELISA. All antibodies were purchased from
Southern Biotechnology (Birmingham, AL).
Immulon 2 plates (Thermo Labsystems,
Franklin, MA) were coated with 5.0 µg/mL
goat anti-mouse IgG2a unlabeled antibody in
PBS for 1 hr at 37°C. After washing, plates
were blocked in PBS/0.05% Tween-20
(PBST) for 30 min at 37°C. Plates were incu-
bated with either IgG2a standard or diluted
supernatants from LPS-stimulated spleen cells
for 2 hr at 37°C. After washes with PBST,
1µ g/mL biotinylated goat anti-mouse IgG2a
antibody was added to each well and incu-
bated for 1 hr at 37°C. Plates were washed
with PBST, and HRP-avidin was added to
each well and incubated for 1 hr at room tem-
perature. After washing, the plates were devel-
oped using ABTS-peroxidase substrate
(Bio-Rad, Hercules, CA) and read after 5 min
in a Bio-tek EL312e automated plate reader
set at dual wavelengths of 405 and 630 nm.
The concentration of IgG2a was calculated
using the IgG2a standard curve in Excel.
Statistics. Results are reported as mean ±
SEM unless otherwise noted. For the in vitro
and in vivo studies involving C57BL/6 mice,
results were analyzed using a paired Student’s
t-test. Because of the greater variability within
the untreated control NZB/NZW mice,
results of studies involving NZB/NZW mice
were analyzed using the nonparametric Mann-
Whitney U-test using SPSS 11 software for
Macintosh (SPSS, Chicago, IL).
Results
IFN-γ production decreases in BPA-treated
mice. Initially we tested the in vitro effects of
the ER-binding molecule BPA on immune
function using the estrogen-sensitive C57BL/6
strain. BPA induced a dose-dependent decrease
in mitogen-stimulated IFN-γ secretion by
splenocytes from both male and female
6-week-old C57BL/6 mice (Figure 1).
To investigate the effect of in vivo exposure
to low doses of BPA on IFN-γ production, we
fed C57BL/6 mice 2.5 µg BPA/kg bw daily for
7 days. This dose was based on previously pub-
lished in vivo studies demonstrating reproduc-
tive effects from microgram doses of BPA per
kilogram body weight and the detection of
microgram levels of BPA in commonly used
food containers (Brotons et al. 1995; Gupta
2000). The mice were sacriﬁced 2–4 days after
the last dose of BPA. There was a consistent
and significant reduction of approximately
40% in ConA-stimulated IFN-γ production in
male C57BL/6 mice treated in vivo with BPA
(Figure 2). Control males produced 46,539 ±
6,837 pg/mL IFN-γ (n = 12) compared with
28,136 ± 4,506 pg/mL in BPA-fed males
(n = 12; p < 0.01). Unstimulated cells produced
undetectable levels of IFN-γ.
Female C57BL/6 mice in both treated
and control groups consistently produced
more IFN-γ than did the males in response to
ConA stimulation (Figure 2). However,
ConA-stimulated splenocytes from female
C57BL/6 mice fed BPA for 7 days produced
28% less IFN-γ compared with untreated
female controls (Figure 2; p < 0.05, paired
Student’s t-test). Control females produced
57,438 ± 2,955 pg/mL IFN-γ compared with
41,592 ± 6,559 pg/mL in the BPA-fed group
(p < 0.05). To test a more physiologic stimu-
lus, splenocytes from an additional 12 female
mice were incubated with heat-killed, gram-
positive S. epidermidis. BPA exposure signiﬁ-
cantly reduced IFN-γ production by 24%
(49,212 ± 3,815 pg/ml IFN-γ vs. 37,478 ±
3,264 pg/mL IFN-γ, p < 0.05; Figure 2).
Lymphocyte distribution in C57BL/6 mice.
To determine whether the reduction in IFN-γ
observed in BPA-fed mice was due to altered
lymphocyte subset distribution, we analyzed
C57BL/6 splenic mononuclear cells for expres-
sion of the T-cell subset markers CD4 and
CD8 and the B-cell marker CD19 by flow
cytometry. Immediately upon isolation, the
cells were stained with ﬂuorescent monoclonal
antibodies and analyzed by gating on live cells.
Compared with control mice, both male and
female BPA-treated mice showed a nonsigniﬁ-
cant trend toward an increase in the percentage
of CD19+ cells (Table 1). The T-cell subsets
did not differ signiﬁcantly between treated or
control mice for either sex.
Although subset distribution did not dif-
fer with BPA treatment, C57BL/6 mice
exposed to BPA for 7 days demonstrated a
significant increase in total splenic mono-
nuclear cells after separation by density cen-
trifugation. The mean number of splenic
mononuclear cells isolated from 32 BPA-fed
mice was 51.7 × 106 ± 2.9 × 106 cells com-
pared with 40.8 × 106 ± 2.8 × 106 cells in
32 age- and sex-matched control mice (p <
0.01, unpaired Student’s t-test).
Cytokine changes in BPA-treated
NZB/NZW mice. IFN-γ contributes to disease
progression in lupus (Hasegawa et al. 2002).
After observing modulation of IFN-γ produc-
tion in C57BL/6 mice, we were interested in
studying the effects of BPA in NZB/NZW
mice. Ten-week-old female NZB/NZW mice
fed BPA at 5 weeks of age showed a signiﬁcant
reduction in ConA-stimulated IFN-γ produc-
tion before the onset of proteinuria symptoms
(Figure 3A). BPA-fed mice with < 100 mg/dL
protein in urine produced an average of 16%
less IFN-γ than did the control untreated mice
(p < 0.05, Mann-Whitney). To determine
whether the reduction in IFN-γ persisted over
the course of several months, we also tested
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Table 1. Lymphocyte subset distribution in C57BL/6 and NZB/NZW mice.
C57BL/6 males C57BL/6 females NZB/NZW femalesa
Control (n = 6) BPA (n = 6) Control (n = 6) BPA (n = 6) Control (n = 12) BPA (n = 12)
CD4+ 26.7 ± 5.9 23.6 ± 5.3 22.4 ± 1.5 21.4 ± 2.0 32.1 ± 3.6 31.3 ± 3.4
CD8+ 19.9 ± 7.3 14.9 ± 2.6 15.5 ± 2.9 13.8 ± 2.8 17.9 ± 2.1 17.5 ± 1.4
CD19+ 33.0 ± 6.0 37.2 ± 6.5 36.8 ± 7.2 43.4 ± 4.2 34.7 ± 5.2 37.3 ± 5.2
aNZB/NZW mice analyzed before proteinuria developed (< 100 mg/dL protein in urine).
Figure 3. Release patterns of IFN-γ (A) and IL-10 (B) in 5-week-old female NZB/NZW mice fed PBS (control) or
2.5 µg BPA/kg bw/day for 7 days and monitored for proteinuria. The without-proteinuria group (n =6   control;
n =6   BPA treated) was sacriﬁced at 10 weeks of age, before development of proteinuria, and ConA-stimulated
splenic supernatants were analyzed for cytokine production by ELISA. The with-proteinuria group developed
proteinuria before cytokine analysis [for IFN-γ, n= 5 control and n=5  BPA treated (supernatants were not avail-
able for all mice for INF-γ); for IL-10, n= 8 control and n=8  BPA treated]. 
*p < 0.05, Mann-Whitney.
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sacrificed at the onset of proteinuria. A dra-
matic 64% reduction in IFN-γ was observed
in ConA-stimulated splenocytes from BPA-fed
mice at disease symptom onset (Figure 3A).
The BPA-treated NZB/NZW mice produced
an average of 6,640 pg/mL IFN-γ versus
18,186 pg/mL in the controls, a difference
approaching statistical signiﬁcance (p = 0.08,
Mann-Whitney).
IL-10 is a second cytokine that is both
implicated in the development of lupus and
modulated by estrogen (Kanda and Tamaki
1999; Yin et al. 2002). We analyzed whether
in vivo BPA exposure could alter IL-10 levels
in female NZB/NZW mice. Before disease
symptom onset, at 10 weeks of age, both con-
trol and BPA-fed mice produced similar
amounts of IL-10 (Figure 3B). Control
NZB/NZW mice produced 276 ± 52 pg/mL
versus 288 ± 59 pg/mL IL-10 in BPA-fed ani-
mals. As disease progressed, both control and
BPA-fed mice produced higher levels of IL-10.
Measuring IL-10 production at the time mice
developed proteinuria demonstrated that the
BPA-fed mice produced 32% less IL-10 than
did controls (699 ± 114 pg/mL vs. 1,097 ±
146 pg/mL, p < 0.05).
IgG2a production decreases in BPA-
treated NZB/NZW mice. In mice, IFN-γ plays
a role in isotype switching to the complement-
fixing antibody class IgG2a, contributing to
the glomerulonephritis associated with lupus
(Zeng et al. 2000). We were interested in see-
ing whether the decreased release of IFN-γ
observed in NZB/NZW BPA-fed mice
resulted in altered IgG2a production. We
measured IgG2a production in LPS-stimulated
splenocytes from NZB/NZW female mice
between 8 and 19 weeks of age by isotype-
specific ELISA. All mice tested negative for
proteinuria (< 100 mg/dL protein in urine). As
shown in Figure 4, lymphocytes from BPA-
treated animals (n = 16) produced signiﬁcantly
less IgG2a than age-matched controls (n = 16;
p < 0.05, Mann-Whitney). The median IgG2a
concentration was 10.4 ng/mL for BPA-fed
mice compared with 23.0 ng/mL for untreated
controls. The BPA-fed NZB/NZW mice pro-
duced a much narrower range of secreted
IgG2a compared with the untreated control
animals. The mean concentration of IgG2a for
BPA-fed animals was 14.4 ± 3.2 ng/mL
(including the one outlier; Figure 4) versus
29.0 ± 5.6 ng/mL in the untreated controls, a
reduction of 50%.
To eliminate the possibility that the reduc-
tion of IgG2a in BPA-treated mice was due to
a decreased percentage of B cells, we analyzed
splenocytes for lymphocyte subsets by flow
cytometry. The subset analysis was performed
on the same NZB/NZW mice used in the
IgG2a assays, with the exception of eight mice
whose splenocytes were not stained. On aver-
age, BPA-fed mice had the same percentage of
CD19+ cells compared with untreated mice
(Table 1). As observed in the C57BL/6 mice,
there was a significant increase in the total
number of mononuclear cells isolated from
the spleens of these BPA-treated mice (n = 16)
by density centrifugation (43 × 106 ± 2.9 ×
106 vs. 34 × 106 ± 2.8 × 106, p < 0.05).
Delay in disease onset observed in BPA-
treated NZB/NZW mice. To analyze whether
in vivo BPA exposure modulates the course of
lupus, we fed BPA to three separate groups of
5- to 6-week-old female NZB/NZW mice for
7 days. Each group consisted of ﬁve BPA-fed
mice and ﬁve control mice. In each of the three
experiments, a control NZB/NZW mouse was
the ﬁrst to develop proteinuria. Overall, female
BPA-treated NZB/NZW mice showed an
average delay of 7 weeks in the onset of pro-
teinuria compared with untreated controls
(Figure 5). The earliest onset of disease symp-
toms was at 26 weeks in a control mouse,
whereas the earliest BPA-treated mouse to
develop proteinuria was 33 weeks of age. On
average, the mice treated with BPA remained
symptom-free for 45 weeks compared with
38 weeks in control animals. Two of the BPA-
fed mice showed no signs of proteinuria at
72 weeks of age. Seven days of oral BPA expo-
sure at a young age appears to modulate the
course of disease in female NZB/NZW mice.
Discussion
Although the biologic effects of BPA are not
clearly understood, its ability to bind both ER
isoforms makes it a potentially important
modulator of immunity. Although estrogen
increases IFN-γ production (Karpuzoglu-Sahin
et al. 2001), we observed an inhibitory effect of
BPA on IFN-γ secretion in both male and
female C57BL/6 and female NZB/NZW
mice. There is evidence that the outcome of
transcriptional regulation at AP-1 or ERE sites
is dependent both on the ER subtype involved
and on the ligand (Mor et al. 2003; Paech
et al. 1997). For example, when tamoxifen is
bound to ER-β, it regulates AP-1 sites in a
manner opposite to that of estrogen (Paech
et al. 1997). Similarly, BPA may act differently
than estrogen when bound to ER-α and/or
ER-β, for example, by down-modulating the
IFN-γ promoter.
In our studies, BPA acts in a protective
manner in lupus-prone mice. It is likely that
the decreased production of IFN-γ in BPA-fed
mice contributed to a substantial reduction in
isotype switching to IgG2a and to the pro-
longed symptom-free period we observed in
BPA-fed NZB/NZW mice. Anti-dsDNA anti-
bodies are a hallmark of disease in lupus-prone
mice (Walker et al. 1996). Typically, anti-
dsDNA antibodies of the IgG classes are not
routinely detected until after 5 months of age
(Yoshida et al. 2002). We were not able to
detect IgG2a anti-dsDNA antibodies in the
NZB/NZW mice used for antibody analysis
because the mice were sacriﬁced between 8 and
19 weeks of age. Recently, we analyzed LPS-
stimulated splenocytes isolated from 8-month-
old female NZB/NZW mice that had been fed
BPA for 1 week beginning at 5 weeks of age.
All mice tested negative for proteinuria. BPA-
fed mice demonstrated a 40% reduction in
IgG2a anti-dsDNA antibodies as detected by
ELISA (Sawai C. Unpublished data).
IL-10 is associated with lupus in both
mice and humans (Gonzalez-Amaro et al.
1998; Llorente et al. 1995; Yin et al. 2002),
yet its role in the disease appears to be com-
plex. IL-10 may act as a regulatory cytokine
that increases as a consequence of the disease
process; alternatively, it may function as a con-
tributing factor to disease (Moore et al. 2001).
Knocking out the IL-10 gene in the lupus-
prone MRL-Faslpr mouse strain indicates that
IL-10 plays a protective role early in disease;
IL-10 is known to inhibit IFN-γ synthesis,
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Figure 4. IgG2a production in young female
NZB/NZW mice fed BPA (n = 16) or PBS control
(n = 16) daily for 7 days at 5 weeks of age and sacri-
ficed between 8 and 19 weeks of age. IgG2a was
detected by isotype-specific ELISA in 72-hr LPS-
stimulated splenic cell supernatants. All mice
tested negative for proteinuria. The box represents
the middle 50% of values; the line inside the box
indicates median; bars indicate range; and the open
circle represents an outlier.
*p < 0.05, Mann-Whitney. 
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Figure 5. Development of proteinuria in 5- to
6-week-old female NZB/NZW mice fed PBS (n = 15)
or BPA (n = 15) daily for 7 days. 
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lower IgG2a concentrations and fewer disease
symptoms (Yin et al. 2002). However, in later
stages of disease, high levels of IL-10 may con-
tribute to disease progression, and anti-IL-10
antibodies delay onset of symptoms (Yin et al.
2002). A 1-week course of BPA treatment had
no apparent effect on IL-10 production in
young female NZB/NZW mice tested before
the onset of proteinuria several weeks after
treatment. Once proteinuria developed, how-
ever, BPA-fed animals produced signiﬁcantly
less IL-10 than did controls. To better under-
stand the relationship between BPA and
IL-10, we plan to analyze IL-10 production in
female NZB/NZW mice in the days immedi-
ately after BPA treatment.
More than 8 months after treatment,
BPA-fed NZB/NZW mice demonstrated a
delay in proteinuria development as well as a
significant reduction in IFN-γ production.
The inhibition of IFN-γ by BPA appears to be
long lasting and may be due to remodeling of
the IFN-γ promoter. Recruitment of the his-
tone acetylase CBP (CREB-binding protein)
to a promoter contributes to increased tran-
scription (Valapour et al. 2002). Both the
nuclear factor-κB (NF-κB) and ER-α path-
way use CBP (Harnish et al. 2000; Kushner et
al. 2000). NF-κB is a critical transcription fac-
tor for several cytokine genes, including IFN-γ
(Sica et al. 1997). BPA bound to the ER may
sequester proteins such as CBP required for
NF-κB–induced cytokine gene expression,
thereby reducing cytokine production.
Alternatively, a recent report indicates that
BPA activates the transcription factor CREB
(Quesada et al. 2002). Expression of the IFN-γ
promoter is down-regulated by CREB-ATF1
proteins binding to both proximal and distal
elements and competing for binding with
Jun/ATF2 proteins (Penix et al. 1996; Zhang
et al. 1998). Activation of CREB due to BPA
exposure may explain the diminished produc-
tion of IFN-γ. We are currently addressing the
possible molecular mechanism for BPA reduc-
tion of IFN-γ production. Our studies suggest
that a low-dose, short-term exposure to the
ER-binding molecule BPA affects murine
immune function in vivo and may have
important implications for modulating
autoimmunity.
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